The relevance of preclinical studies for the treatment of Parkinson's disease

Journal of Neurology, Supplement

Volumn 250, Issue 1, 2003, Pages

  Gerlach, Manfred ^a   Foley, P ^a   Riederer, P ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Catechol O methyltransferase (COMT) inhibitors; L DOPA therapy; Neuroprotection; Parkinson therapy; Selegiline; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; SELEGILINE; TOLCAPONE;

CLINICAL STUDY; CLINICAL TRIAL; DRUG SAFETY; ENZYME INHIBITION; HUMAN; NEUROPROTECTION; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANTIPARKINSON AGENTS; BENZOPHENONES; DRUG EVALUATION, PRECLINICAL; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; NITROPHENOLS; PARKINSON DISEASE; SELEGILINE;

EID: 0037327713     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133:1706-1707
2. Barbeau A, Sourkes TL, Murphy GF (1962) Les catecholamines dans la maladie de Parkinson. In: de Ajuriaguerra J (ed) Monoamines et Systeme Nerveux Central. Masson & Cie, Paris, pp 247-262
3. Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanineffekt bei der Parkinson-Akinese. Wien Klin Wschr 73:787-788
4. Birkmayer W, Mentasti M (1967) Weitere experimentelle Untersuchungen über den Katecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Choreasyndrom). Arch Psych Z ges Neurol 210:29-35
5. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36:303-326
6. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: a longterm study. J Neural Transm 64:113-127
7. Carlsson A, Lundqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
8. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism: chronic treatment with L-DOPA. New Engl J Med 280:337-345
9. Dangoumau JA (1996) From discovery to market availability. In: Wermuth CG (ed) The Practice of Medicinal Chemistry. Academic Press, London, pp 847-862
10. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extra-pyramidalen Systems. Wien Klin Wschr 38:1236-1239
11. Elizan TS (1993) (-)-Deprenyl combined with L-Dopa in the treatment of Parkinson's disease. In: Szelenyi I (ed) Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders. Birkhäuser Verlag, Basel Boston Berlin, pp 277-288
12. Foley P (2000) The L-DOPA story revisited. Further surprises to be expected? The contribution of Isamu Sano to the investigation of Parkinson's disease. Adv Res Neurodegeneration 8:1-20 (= J Neural Transm (Suppl 60):1-20)
13. Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol (Molec Pharmacol) 226:97-108
14. Gerlach M, Youdim MBH, Riederer P (1996) Pharmacology of selegiline. Neurology (Suppl 3) 47:S137-S145
15. Green AR, Mitchell B, Tordorff A, Youdim MBH (1977) Evidence that dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of enzyme inhibition necessary to increase functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 160:343-349
16. Haasio K, Sopanen L, Vaalavirta L, Linden IB, Heinonen EH (2001) Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm 108:79-91
17. Hornykiewicz E (2002) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17:501-508
18. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155:154-164
19. Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393-408
20. McNeely W, Davis R (1997) Entacapone. CNS Drugs 8:79-88
21. Nissinen E, Kaheinen P, Penttilä KE, Kaivola J, Lindén I-B (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 340:287-294
22. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 46:1359-1365
23. Sano I, Gamo T, Kakimoto Y, Tamiguchi K, Takegada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32:586-687
24. Spencer CM, Benfield P (1996) Tolcapone. CNS Drugs 5:475-481
25. Squires RF (1972) Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 5:355-370
26. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522
27. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-1371
28. Youdim MBH, Collins GGS, Sandler M, Pare CBM, Bevan-Jones AB, Nicholson WJ (1972) Human brain monoamine oxidase: multiple forms and selective inhibition. Nature 236:225-228